로딩 중…
지수 로딩 중…
이뮨온시아
424870· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,865-6.87%
2026-06-19
Price Chart
이뮨온시아-19.48%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 352.77B KRW |
| Revenue | 111.2M KRW |
| Net Income | -13.92B KRW |
| Total Assets | 33.15B KRW |
| Net Assets | 28.42B KRW |
| Value | |
| P/B | 12.41x |
| FCF Yield | -6.54% |
| Profitability | |
| ROE | -48.99% |
| ROA | -42.00% |
| Op. Margin | -25182.04% |
| Financial Health | |
| Debt Ratio | 16.65% |
| Total Debt | 0 KRW |
| FCF | -23.06B KRW |
| Cash | 8.24B KRW |
| Current Ratio | 6.22x |
| Performance | |
| 1Y Return | -19.48% |
| 1M Return | -26.94% |
| From 52W High | -75.06% |
| 1Y MDD | -73.88% |
| Trading | |
| Volume | 732,369 shares |
| Foreign Own. | 2.88% |
| Per Share | |
| EPS | -346 KRW |
| BPS | 289 KRW |
Company Info
IMMUNEONCIA, established in 2016, is a specialized company developing antibody-based immune-oncology drugs, slated for KOSDAQ listing in 2025 as a technology growth company. It holds Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies as core assets, generating revenue through new drug candidate development and early clinical technology transfers. IMMUNEONCIA aims to be the first domestic leader in commercializing Anti-PD-L1 immune-oncology drugs and is concentrating on research and development to launch global blockbuster new drugs. Its headquarters are located in Yongin-si, Gyeonggi-do.